Carboxylic acids, e.g. valproic acid (A61K31/19)

Amid derivatives of n-carbamide-substituted amino acids as modulators of formylpeptide receptor-1 (fprl-1) // 2629205
FIELD: chemistry.SUBSTANCE: invention relates to a compoundd represented by the formula , its enantiomers, diastereoisomers or pharmaceutically acceptable salts, which have modulatory activity against N-formylpeptide receptor-1 (FPRL-1). In formula II, a is 1, b is 0 or a is 1, b is 1; R1 is -OH; R2 is C1-8 Alkyl, optionally substituted by C6-10 aryl, amide or heterocycle, wherein the heterocycle is a 3 to 10-membered aromatic ring which contains at least one heteroatom selected from nitrogen, wherein one methylene group in the alkyl can be replaced by sulfur or sulphonyl; R3 is hydrogen or halogen; R4 is hydrogen; R5 is a halogen, -CF3 Or -S (O)nR14; N is 0, 1 or 2; R6 is hydrogen; R7 is hydrogen or halogen; R8 is hydrogen or C1-8 Alkyl; R9 is hydrogen, C1-8 Alkyl, Optionally substituted with a hydroxyl group, or C6-10 aryl; R10 is hydrogen, C1-8 alkyl optionally substituted with a hydroxyl group, or C6-10 aryl; R9a is hydrogen or C1-8 alkyl optionally substituted with a hydroxyl group; R10a is hydrogen or C1-8 alkyl optionally substituted with a hydroxyl group; R14 is CF3 or C1-8 alkyl.EFFECT: increased activity of derivatives.12 cl, 5 tbl, 4 ex
ethod for obtaining of stabilized pharmaceutical composition as aqueous solution // 2629204
FIELD: pharmacology.SUBSTANCE: invention relates to a method for preparation of a stabilized pharmaceutical composition in the form of an aqueous solution which can be used to prepare a drug for intravenous administration containing succinic acid, nicotinamide, inosine and riboflavin mononucleotide sodium as active components and having cytoprotective properties. In the method for preparation of a stabilized pharmaceutical composition in the form of an aqueous solution containing succinic acid, inosine, nicotinamide, riboflavin sodium mononucleotide as active components, by dissolving them in water with subsequent sterilizing filtration, the followin is further added to the composition as a stabilizing agent: one or more pharmaceutically acceptable components selected from the group consisting of sodium hydroxide, trisoxymethylaminomethane (TRIS), ethanolamine, diethanolamine, sodium carbonate, meglumine, to obtain a stable solution with pH in the range of 6.0 to 8.0 in the following ratio, wt %: succinic acid 5.00-12.50; inosine 1.00-2.40; nicotinamide 0.50-1.20; riboflavin mononucleotide sodium 0.10-0.24; stabilizing agent 3.21-51.30; water to 100.0%, and further thermal sterilisation of the solution at a temperature of 100°C and exposure time of 8 min to 116°C and exposure time of 2 min.EFFECT: increased method application safety due to thermal sterilisation.3 cl, 96 ex, 5 tbl
ethod for coagulopatic bleeding prevention during cesarean section // 2629040
FIELD: medicine.SUBSTANCE: to prevent bleeding during caesarean section, when performing a cut of the anterior abdominal wall during caesarean section, 10 ml of 10% calcium gluconate solution and 10 ml of tranexamic acid containing 1 gram of dry matter are subsequently injected into a peripheral vein.EFFECT: method provides prevention of coagulopathic bleeding with a decrease in perioperative blood loss in patients at risk of such bleeding.8 tbl, 6 ex
ethod of intraoperative warning of local ischemic damage to brain at microsurgeric operation on cerebral arterial aneurysis // 2629019
FIELD: medicine.SUBSTANCE: for intraoperative prevention of local ischemic brain damage during microsurgical surgery for cerebral arterial aneurysms, anesthesia, intraoperative therapy, with preventive temporary cloning of an aneurysm and an intravenous drip of cytol flavin are performed. At the stage of surgical access to the aneurysm, the preparation of cytoflavin is injected intravenously in drops of 10 ml in dilution with 200 ml of physiological solution for 30 minutes. In this case, a temporary clip with short intervals of vessel occlusion is applied to the feeding aneurysm of the artery.EFFECT: invention makes it possible to reduce the occurrence of complications during clipping of an aneurysm, to increase the tolerance of occlusion of the artery and to reduce the recovery postoperative period.1 tbl, 1 ex
eans for capillary skin disorders (telangiectasias) removal // 2629018
FIELD: cosmetology.SUBSTANCE: invention is an agent for telangiectasias treatment comprising a hydrolase class enzyme subtilisin, troxerutin, disodium edetate stabiliser, trolamine, carbomer and water, the components in the agent being in a certain ratio %.EFFECT: painless and safe decolouration of intradermal veins walls and improved results of telangiectasias treatment.5 cl, 3 ex

Composition containing buffered lactic acid // 2628534
FIELD: pharmacology.SUBSTANCE: group of inventions refers to medicine, specifically to lubricating compositions containing buffered lactic acid with pH in the range of 3.0 to 6.5. The composition has an aqueous activity of 0.10 to 0.50 and the predetermined aqueous activity is obtained by drying.EFFECT: when the absorbent article contacts the skin or mucous membrane of the user, the friction between the absorbent article and the skin or mucosa decreases, the composition has a pH value in the range corresponding to acids that is close to the pH of skin or mucous membrane.13 cl, 9 dwg, 3 tbl, 1 ex
ethod for heterotopic ossification surgical treatment with local neural simulation of spastic syndrome // 2628370
FIELD: medicine.SUBSTANCE: for surgical treatment of heterotopic ossification with local neural simulation of the patient spastic syndrome, preliminary multilayer spiral computerized tomography (CT) is used to ptovide spatial imaging of bone structures and ossificates. The method of magnetic resonance imaging reveals the ossificate soft tissue component which is not visualized by MSCT. Then the heterotopic ossificate maturity stage is determine by calcium-phosphorus metabolism indices - alkaline phosphatase, osteocalcin, and bone matrix formation marker PINP - N-terminal pro-peptide of type 1 procollagen in patient's venous blood. If the measured parameters of N-terminal propeptide of type 1 procollagen - PINP are less than 76 ng/ml, even in case of an isolated lesion of one elbow or knee joint, alkaline phosphatase level is in the range 40-150 U/l and osteocalcin level is within 11-46 ng/mL, completion of osteoid formation and mineralization with formation and maturation of newly formed cancellous bone is concluded. In this case, surgical ossificates removal from the affected joint is prescribed. At that, local neural simulation of spastic syndrom is performed prior to surgical removal of ossificates, until it a stable decrease to the level of 0 to 1 on Ashworth scale is reached. Next, surgical treatment is performed involving ossificate resection or removal of an adequate volume of heterogeneous bone to restore the functionally adequate range of motion in the affected joint.EFFECT: possibility of surgical treatment of heterotopic ossification in patients with spastic syndrome, minimizing the risk of complications during surgical treatment, and pathological process recurrence.3 cl, 5 ex
Hemostatic sponge (versions) // 2627855
FIELD: medicine.SUBSTANCE: invention is a hemostatic sponge containing a base and iron salts as an active substance, characterized by the base and active substance being freeze-dried, while the sponge contains sodium alginate as the base, and iron sulfate as the active ingredient, the components in the sponge are in a certain ratio in the final aqueous solution, in the volume of 1 litre in %.EFFECT: expanded assortment of hemostatic sponges with pronounced hemostatic action and exclusion of direct adverse effect of the active substance on the wound surface and surrounding tissues due to the pharmacological form of the sponge.4 cl, 37 ex
ethod of producing nanocapules of l-arginine // 2627819
FIELD: nanotechnology.SUBSTANCE: method is characterized in that L-arginine is slowly added to a suspension of carrageenan in butyl alcohol in the presence of 0.01 E472c preparation as a surfactant with stirring at 1300 rpm. Then 5 ml of hexane are poured, the resulting suspension of the nanocapsules is filtered off and dried at room temperature. The mass ratio core: the shell is 1:3 or 1:1.EFFECT: simplification and acceleration of the process of obtaining nanocapsules.3 ex
Amino acids composition for methanol poisoning prevention and treatment // 2627610
FIELD: pharmacology.SUBSTANCE: amino acid composition from a group of natural or synthetic hydrophobic compounds that are alcohol dehydrogenase (ADH) inhibitors and contain D- and L-amino acids in the following component ratio, wt %: tyrosine 10-19.5, valine 13-22, leucine 14-24, alanine 4.0-23.3, tryptophan 1.7-36, proline 9.2-19 as active ingredients for the detoxification of methanol.EFFECT: composition acts as an antidote that completely removes acute methanol poisoning, possesses protective properties, exhibiting a pronounced inhibitory effect of ADH activity on methanol oxidation, and significantly reduces the amount of highly toxic secondary metabolites.7 cl, 4 ex, 1 tbl
ethods for cancer treatment using autophagy inhibitor based on thioxanthone // 2627588
FIELD: medicine.SUBSTANCE: autophagy inhibitor based on thioxanthone is used to manufacture a medicament for cancer treatment in combination with an autophagy-causing compound. A pharmaceutical composition and a pharmaceutical kit for cancer treatment containing an autophagy inhibitor based on thioxanthone and an autophagic compound are also provided.EFFECT: increased anticancer activity of therapy due to decreased cell viability and increased apoptosis.8 cl, 26 dwg, 7 ex

Pharmaceutical compositions comprising oligomeric lactic acid // 2627470
FIELD: pharmacology.SUBSTANCE: invention provides a composition comprising i) an oligomeric lactic acid of formula (I) wherein n is an integer from 2 to 20, 2 to 19, or 2 to 18, and wherein the content of the oligomeric lactic acid which is a trimer, i.e, HL3, which coefficient n is 2, is approx. 10 to approx. 20 wt % of the oligomeric lactic acid total weight. The average molecular weight Mn of the oligomeric lactic acid is approx. 200 to approx. 500, and ii) a mucoadhesive agent. The oligomeric lactic acid content is 20 to 80 wt % and mucoadhesive agent content is from 10 to 65 wt %.EFFECT: improved properties.17 cl, 11 ex, 25 tbl, 9 dwg
ethod for correction of lipid peroxidation processes in patients with acute myocardial infarction // 2627458
FIELD: medicine.SUBSTANCE: 30 minutes before recanalization, patients receive 20 ml of Cytoflavin solution diluted in 250 ml of 5% glucose solution intravenously for 30 minutes by drop infusion.EFFECT: invention provides a stabilizing effect on peroxidation processes, increases the antioxidant system activity, providing prevention of reperfusion injury and improving the functional state of the ischemic myocardium.2 tbl, 2 ex
ethod of lichen planus treating // 2627456
FIELD: medicine.SUBSTANCE: invention can be used to treat lichen planus (LP). The method includes taking a patient of prednisolone in an average daily dosage (SDS) of 30 mg, hydroxychloroquine in the SSD of 400 mg, mebhydroline in a 200 mg SDO, 25 mg of hydroxysine, external betamethasone cream. In addition, the patient additionally takes Noophen in a dose of 250-500 mg, three times, after meals, with the first reception of Noophen preparation prescribed for 3 hours before a single daily session of TPP therapy with bipolar current in the 70 Hz mode, starting at a current of at least 2.0 MA, in each subsequent procedure the current is increased by 0.2-0.4 mA, under the control of the clinical effect and the patient's condition after each procedure, the procedure time is 30-40 min, the course is 6-12 procedures.EFFECT: use of the invention makes it possible to shorten the time of systemic and topical application of hormonal drugs, to achieve a longer remission; eliminate cosmetic defects, improve the quality of life of patients.2 ex
ethod of treatment of obstructive bronchitis in dogs // 2627446
FIELD: veterinary medicine.SUBSTANCE: method involves the treatment with Vasotop P, a course of 1-2 months. Treatment of obstructive bronchitis with bacterial, viral and parasitic etiology is carried out in two stages, including the use of immunostimulants in the first stage with the administration of etiotropic therapy with antibiotics and/or antiparasitic drugs; in the second stage, the use of bronchodilators with the simultaneous use of Vasotop P at a dose of 0.125 mg per 1 kg Mass of the animal, and in the presence of relapse - for life. In another embodiment, the method comprises using Veroshpiron in capsules at a dose of 100 mg per dog 20 kg Course 5-7 days; Vasotope P at a dose of 0.125 mg per 1 kg Weight of the animal, course 1-2 months, and at the terminal stage of life and Riboxin + glucose of 2.5 ml per dog 20 kg 1 time per day, 3 days, intravenously.EFFECT: highly effective treatment of dogs with obstructive bronchitis on the background of chronic cardiac and renal insufficiency.2 cl, 1 dwg, 1 ex
Pharmaceutical preparation for rheumatological diseases treatment // 2627424
FIELD: pharmacology.SUBSTANCE: pharmaceutical preparation in the form of a solution for use in rheumatological diseases treatment contains a combination comprising sodium diclofenac or naproxen sodium, betamethasone sodium phosphate and hydroxy-cobalamin sulfate as active substances and benzyl alcohol, propylene glycol, sodium metabisulphite and water for injection as auxiliary components. A method for production of the preparation is described as well.EFFECT: stable, effective formulation with analgesic, anti-inflammatory and antineurotic effects.4 cl, 1 tbl, 4 ex

ethod of obtaining nanocaphul l-arginine in the hellan samples // 2626831
FIELD: nanotechnology.SUBSTANCE: L-arginine is used as the nucleus, and gellan gum is used as the envelope of nanocapsules at the mass ratio of the core: shell 1:1, 1:2, or 1:3, respectively. The method is that L-arginine is slowly added to a suspension of gellan gum in butyl alcohol in the presence of 0.01 E472c preparation as a surfactant with stirring at 1,300 rpm. Then 5 ml of diethyl ether are poured, the resulting suspension is filtered off and dried at room temperature.EFFECT: nanocapsules production process simplification and acceleration, reduction of losses during the nanocapsules production.1 dwg, 4 ex
eans for polyps treatment in sinuses and prevention of their repeated growth, and method of its application // 2626829
FIELD: medicine.SUBSTANCE: method for polyps treatment in the sinuses is proposed. The method is characterized by application of aqueous solutions of acetic acid in concentrations of 3-6% as means or drug component for the treatment of polyps in the nose sinuses, and 1-2 drops of solution are injected into each sinus within 1-2 weeks, 3-5 times a day.EFFECT: improved safety and effectiveness of polyps treatment in the sinuses, prevention of repeated growth, reduced duration and costs of treatment.3 ex
Composition for physical stability and operability increase // 2626823
FIELD: pharmacology.SUBSTANCE: composition contains alpha-tocopherol acetate, retinol acetate, succinic acid and chocolate mass at the following ratio of the components, wt %: retinol acetate - 2.1-4.5; alpha-tocopherol acetate - 0.35-0.75; succinic acid 0.25-0.65; chocolate mass - the rest.EFFECT: composition according to the invention has good taste qualities, has a convenient form for administration, provides an increase in efficiency and physical endurance in a short time by taking a complex of active substances optimally selected and in an amount sufficient to achieve the maximum effect.2 tbl, 3 ex
Water-based liquid composition with bromfenac possessing preservative effectiveness // 2625755
FIELD: chemistry.SUBSTANCE: invention represents the use of bromfenac or its salt to improve the preservative effectiveness of the water-based liquid composition, comprising (a) bromfenac or its salt and (b) benzalkonium chloride, and c) at least one agent selected from the group consisting of nonionic surfactant and water-soluble polymer. The invention also relates to a method of improving the preservative effectiveness of the aqueous solution described above, which comprises adding of bromfenac or its salt in an amount of 0.1 w/v % to the solution.EFFECT: invention enables to obtain a composition with imroved preservative activity, wherein there are low concentrations of benzalkonium chloride preserving agent.10 cl, 21 tbl, 4 ex
ethod of correction of the age-related face skin changes // 2625548
FIELD: cosmetology.SUBSTANCE: method includes intradermal injection of the "Hyalual" preparation containing unstabilised hyaluronic acid and succinate. In the treated area, skin tension lines are marked and "Hyalual" 2.2% 1-2 ml is injected in small doses into the middle layer of the derma between the reference zones along the indicated tension lines by retrograde short-line technique, with the needle inserted into the skin at an angle of 30-45° to the middle or 1/3 length.EFFECT: increased effectiveness of correction of the age-related face skin changes by increasing the therapeutic effect of the Hyalual preparation by means of optimising the scheme and techniques of its injection.1 dwg
ethod for personified photodynamic therapy of extensive cosmetic skin defects // 2625297
FIELD: cosmetology.SUBSTANCE: drug based on 5-aminolevulinic acid is applied on the entire face and / or head skin. After 1 hour after drug application on skin, fluorescence spectroscopy is carried out, determining the fluorescence intensity (FI), on the basis of which a dose of laser irradiation for PDT is chosen from the range of 5-45 J/cm2. The lower the FI, the smaller the dose of irradiation. PDT irradiation of the entire skin is carried out using laser radiation with a wavelength of 400-800 nm.EFFECT: method allows to increase the PDT efficiency of extensive cosmetic skin changes due to personified selection of the therapeutic dose of laser irradiation taking into account the quantitative measurement of accumulation level of 5-ALA of induced protoporphyrin IX by fluorescence spectroscopy method.4 dwg, 2 ex
ethod for combined medical and balneological treatment of joint diseases // 2624362
FIELD: medicine.SUBSTANCE: for combined medical and balneological treatment of joint diseases, the patient is treated with medication, including administration of a non-steroidal anti-inflammatory drug and a chondroprotector. At the stage of exacerbation, starting from day 1-3 of medical treatment, the patient is additionally treated with foam and licorice liquor baths with a temperature of 35°C, containing a thick extract of licorice root (LRTE) from 50 to 150 ml. If the patient enters the stage of fading exacerbation, he/she additionally receives foam and vortex baths with a temperature of 36-38°C, containing from 50 to 70 ml of LRTE, starting from day 3-5 of medical treatment. In case if the patient enters the stage of incomplete remission, he/she additionally receives foam-mineral-vortex baths with a temperature of 36-38°C, containing "Dzhemukhskaya Tselebnaya" mineral water instead of fresh water, and LRTE in an amount of 50 to 70 ml, starting from day 5-7 of medical treatment. Bath duration is 10-15 minutes. Baths are performed daily or once in two days, 8-10 per a course of treatment.EFFECT: increased efficiency while reducing the duration of disease treatment.2 tbl, 3 ex
Jasmonate application for bladder function disorders treatment // 2623878
FIELD: medicine.SUBSTANCE: invention relates to a method for treatment of non-psychological stress bladder function disorders, which is a bladder hyperactivity. The method involves administration of at least one jasmonate to a mammal in need of treatment, wherein the jasmonate is jasmone or has the structure (I), where n is 0; R1 represents alkoxy; R2 represents O; R3, R4 and R5 represent H; the bond between C9:C10 represents a double bond.EFFECT: invention provides treatment of urinary bladder hyperactivity.4 cl, 1 ex

New transthyretin-related amyloidosis therapy // 2623062
FIELD: pharmacy.SUBSTANCE: group of inventions is proposed: application of catechol-O-methyltransferase (COMT) tolcapone, entacapone or nitecapone inhibitor for prevention and/or treatment of transthyretin-associated amyloidosis; application of the same compound for manufacture of a medicament for the same purpose; application of the combination of the same compound and an additional medicament selected from the other said COMT inhibitor, or benzoxazole, iodine diflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxycycline and epigallocatechin-3-gallate derivative, for manufacture of a medicament for the same purpose; application of a therapeutic agent selected from the group consisting of benzoxazole, iodine diflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxycycline and epigallocatechin-3-gallate derivative, for manufacture of a medicament for prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with a COMT tolcapone, entacapone or nitecapone inhibitor for prevention and/or treatment of transthyretin-associated amyloidosis.EFFECT: stabilization of transthyretin tetramer and disintegration of transthyretin fibrils.13 cl, 4 dwg, 6 tbl
ethod for macular area morphometric changes treatment in case of polymorbide somatic conditions // 2622759
FIELD: medicine.SUBSTANCE: optical coherent tomography of the retina is used for research. When the macular area relief is flattened and the average central thickness of the retina is increased beyond 300 mcm, diabetic macular edema is diagnosed. In the presence of cystic cavities in the nuclear and plexiform layers of the retina, cystic macular edema is diagnosed. Treatment by a 2.0% dorsopt solution is prescribed every morning and evening in the eye, continuously. In the presence of uneven retina contour and retina folds of irregular shape, membrane epiretinality is additionally diagnosed and instillation of 0.1% diclofenac solution three times a day in the eye during the month is additionally prescribed. Then rest for a month and repeated treatment with diclofenac solution of according to the scheme above. A course of: vinpocetine, pyracetam, detralex is prescribed again with repetition 6 months later.EFFECT: use of the invention makes it possible to increase the effectiveness of treatment of morphometric changes in the macular area with improved state of vitreomacular interface, reduced edema and decreased risk of vitreomacular complications.2 dwg, 1 ex
ethod of treatment of mastitis in lactating cows // 2622017
FIELD: veterinary medicine.SUBSTANCE: method comprises intracisternal injecting of the drug at a dose of 10.0 ml to the affected udder part with 12-hourly intervals 2-4 times. Injectable preparation contains succinic acid, ph-2 ASD, iodine and potassium iodide, the polyvinyl alcohol and procaine at the following component ratio, wt %: Succinic acid 1.0, ASD ph-2 2.0, 0.1 iodine, potassium iodide 0.5, procaine 0.5 polyvinyl alcohol 1.0, purified water is the rest.EFFECT: invention is highly effective for the treatment of mastitis in lactating cows.2 tbl, 3 ex
Composition for stimulation of nonspecific resistance and metabolism of broiler chicks // 2621999
FIELD: veterinary medicine.SUBSTANCE: includes levamisole as immunomodulator, amber acid as a biologically active compound, water soluble salts of iron, copper, zinc, cobalt and water at the following component ratio, wt %: levamisole - 0.75, amber acid - 1.0, ferrous sulfate - 2.0, copper sulfate - 0.2, zinc sulphate - 0.6, cobalt sulfate - 2.0, distilled water - rest. The method includes the use of the claimed composition. The composition dissolved in water as 1:3 is to be given to chickens in the following age periods, days: 5-6; 12-14; 16-18; 20-22; 24-26; 27-35.EFFECT: increase nonspecific resistance and metabolism of meat chickens.2 cl, 4 tbl, 2 ex
ethod of treating patients suffering pulmonary tuberculosis // 2621875
FIELD: medicine.SUBSTANCE: antibacterial therapy is conducted in accordance to standard conditions. From the first day of treatment, also inject Wobenzym daily 1 tablet 30 minutes before meals 2 times a day for 60 days. Additionally, 10 intravenous drip infusions of the drug Reamberin are included in the course of treatment from the first day. Infusions are performed once a day every other day at a dose of 400 ml per infusion.EFFECT: reduction of the periods of resorption of infiltration, closure of cavities of decay, abacillation, reduction in the frequency of formation of adverse hepatotoxic reactions.1 tbl, 2 ex
ethod for non-oncologic cosmetic skin defects photodynamic therapy // 2621845
FIELD: medicine.SUBSTANCE: photosensitizer based on 5-aminolevulinic acid is applied to the affected skin areas. An hour later PDT session is performed on these sites by means of laser radiation with an energy of 30-150 j/cm2, wavelength of 630 nm. 60 minutes after the end of the PDT session, low-intensity laser irradiation with a wavelength of 850-900 nm is conducted on the entire PDT-exposure area. Exposure takes 2 to 25 minutes.EFFECT: method allows to improve the efficiency of PDT for extensive cosmetic changes of skin by reducing inflammatory skin reactions as a result of low-intensity laser irradiation.3 ex

Composition and method of autoimmune diseases treatment // 2621129
FIELD: pharmacy.SUBSTANCE: combination of antibiotics containing rifabutin, clarithromycin and clofazimine for treatment of autoimmune diseases such as multiple sclerosis.EFFECT: increased efficiency of treatment.16 cl, 5 tbl, 12 dwg
Biologically active composition with adaptogenic action // 2620562
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, namely to biologically active composition possessing adaptogenic, cold-protective, antihypoxic action influencing hematological indices of peripheral blood. Biologically active composition, made in form of tablet, possessing adaptogenic, cold-protective, antihypoxic action influencing hematological indices of peripheral blood, contains hemoglobin, succinic acid, coenzyme Q10, riboflavin, ascorbic acid, copper source, cobalt source and auxiliary substances in certain proportions.EFFECT: composition, described above, enables increasing adaptive processes in human body.1 cl, 5 tbl, 1 ex
Energometabolic composition for preventive therapy of metabolic acidosis, ketosis, and iodine deficiency in cows // 2620557
FIELD: agriculture.SUBSTANCE: claimed energometabolic composition for preventive therapy contains beet molasses, succinic acid and citric acid, sodium chloride, iodinol in aqueous solution in the following ratio, wt %: succinic acid - 1,5, citric acid - 0,15, beet molasses - 50, sodium chloride - 2,5, iodinol - 5,0, water - the rest The claimed method involves the use of the claimed composition with the multiplicity of once in 5-7 days by watering animals at a dilution of the composition in water of 1:5-7 or mixing it with the fodder.EFFECT: group of inventions relates to the field of veterinary medicine and is intended for the prevention of metabolic acidosis, ketosis, and hypothyroidism in cows.2 cl, 4 tbl, 1 ex

Content for stimulating metabolic processes, immune system, prevention the diseases and diarrhea // 2620554
FIELD: veterinary medicine.SUBSTANCE: declared composition has metabolic, immunomodulating and antimicrobial activity for preventing gastrointestinal diseases with diarrhea syndrome, comprising succinic acid and SDA iodinol second fraction with the following ratio of components per 1000 ml of aqueous solution: Succinic Acid - 10.0 g iodinol - 250 ml of SDA second fraction - 40 ml. The following is also claimed: composition having metabolic, immunomodulating and antimicrobial activity for preventing gastrointestinal diseases diarrhea syndrome comprising succinic acid, iodinol, levamisole with the following ratio of components per 1000 ml of aqueous solution: Succinic Acid - 10.0 g iodinol - 250 ml , levamisole - 10.0 g.EFFECT: stimulation of metabolism and the immune system, prevention of gastrointestinal diseases, and increase the activity of the growth of young farm animals.2 cl, 6 tbl, 3 ex
Implantable naltrexone tablets // 2620254
FIELD: medicine.SUBSTANCE: implantable naltrexone tablets and method for sterilizing implantable naltrexone tablets are described. The implantable tablet comprises naltrexone in an amount of 500-2000 mg placed in a cavity formed by moulded biodegradable polymer based on DL-lactides and/or DL-glycolides, adding Eudragit pharmaceutical polymer and a lubricant to provide controlled release of the active substance for 3 months or more. The lubricant consists of stearic acid or glyceryl monostearate to prevent tissue irritation and inflammation at the implantation site.EFFECT: implantable naltrexone tablets, free of magnesium stearate and triamcinolone, are obtained, in order not only to reduce the metabolic load on the liver, but also reduce toxicity and carcinogenicity.7 cl, 2 tbl, 6 ex
ethod for prevention and treatment of newborns calves diarrheal diseases // 2619859
FIELD: veterinary medicine.SUBSTANCE: method comprises oral applying of the complex with metabolic agents, immunomodulating and anti-infective effect of 100 ml 30 minutes prior to the drinking colostrum or milk twice a day for 5 days. The cure comprises succinic acid as metabolite, immunopotentiator - antiseptic-stimulator of Dorogov of second fraction (ASD-2) or levamisole, the antimicrobial component - iodinol in the following ratio: succinic acid - 1 g; antiseptic stimulator of Dorogov of second fraction (ASD-2) - 4 ml or levamisole - 0.05 g; iodinol - 30 ml; Boiled water - 100 ml.EFFECT: cure is highly effective for the prevention and treatment of diarrhea of newborn calves.7 tbl, ex 5
Paste for periodontal diseases treatment for patients with diabetes mellitus // 2619848
FIELD: medicine.SUBSTANCE: invention can be used for periodontal disease treatment, including for patients with type II diabetes mellitus (hereinafter referred to as diabetes), adolescents, elderly, pregnant women and lactating women. The poposed paste contains, wt %: 25.0-30.0 of succinic acid, 1.50-2.0 of ascorbic acid, 2.5-5.0 of decamethoxin, 14.0-15.0 of zinc oxide and petrolatum - up to 100. The proposed paste for periodontal disease treatment can be used for diabetic patients belonging to different risk groups.EFFECT: sufficient efficacy of treatment and prevention of complications.3 ex
ethod for periodontal diseases treatment for patients with type ii diabetes mellitus // 2619847
FIELD: medicine.SUBSTANCE: for treatment of periodontal disease in patients with type II diabetes mellitus, an anti-inflammatory drug is administered. "Limontar" diluted in an aqueous alkaline medium is used as an anti-inflammatory drug, which is taken one pill 2-4 times a day 10-30 minutes before meals, for 10-14 days.EFFECT: effective treatment of periodontal disease at diabetes mellitus, and a possibility of method application for diabetic patients belonging to different risk groups.3 ex

Compositions and methods for treatment of osteoarthritis // 2619553
FIELD: veterinary medicine.SUBSTANCE: invention relates to veterinary science and concerns a process for changing the expression of one or more genes in an animal selected from dogs and cats, which are exposed to or is a pathological condition of the joint, which comprises administering to the animal a composition comprising at least one omega-3 fatty acid, at least one glycosaminoglycan, at least one amino sugar, at least one antioxidant, and carnitine or acetylcarnitine, wherein the combined amount of each of these ingredients represent quantity which modulates gene expression.EFFECT: invention provides treatment of the pathological conditions of the musculoskeletal joints and alleviates the symptoms associated with such pathological conditions.8 cl, 17 dwg, 3 tbl, 11 ex
ethod for neuralgia treatment // 2619344
FIELD: medicine.SUBSTANCE: for neuralgia treatment, a drug complex is used, where one of non-steroidal anti-inflammatory compounds drugs is applied as the basic analgesic agents, namely - ketorolac tromethamine at a dose of 15-75 mg, or sodium metamizole at a dose of 500-2500 mg, or the ketoprofen at a dose of 50-250 mg, or dexketoprofen at a dose of 25-125 mg, or lornoxicam at a dose of 4-20 mg, cyanocobalamin at a dose of 500-2500 mcg is used as an adjuvant analgesic agent, and drotaverine hydrochloride at a dose of 10-50 m is used as a myotropic spasmolytic action, that are administered intravenously with distribution of the said doses by one or two daily injectios, course of treatment lasts 1-10 days.EFFECT: method allows to ensure complete elimination of the pain syndrome after the course of treatment, the possibility of pain syndrome elimination with a single administration of drugs with obtaining of a momentary stable analgesic effect by eliminating the protective muscular tension in the affected nerve zone at method safety.2 tbl, 125 ex
ethod of prophylaxis of post-traumotomic pain syndrome in oncosurgery // 2619212
FIELD: medicine.SUBSTANCE: for the prevention of post-thoracotomy pain syndrome (hereinafter - PTPS) in oncosurgery a day before the surgery, anticonvulsant pregabalin is administered orally 75 mg 2 times/day and 75 mg 2 hours before the operation. Then, an epidural catheter is performed on the operating table, through which a three-component mixture is infused throughout the operation: ropivacaine 3 mg/ml+fentanyl 4 mcg/ml+epinephrine 2 mcg/ml at a rate of 5-15 ml/h. Induction of anesthesia is intravenously: fentanyl 0.00004±0.00002 mg/kg, ketamine 0.29±0.13 mg, propofol 0.56±0.31 mg/kg, rocuronium bromide 0.68±0.14 mg/kg. Maintenance of anesthesia: sevoflurane inhalation 0.6-1 MAK in an oxygen-air mixture (FiO2 0.3-0.8), fentanyl 0.00004±0.00002 mg/kg/h, ketamine 0.0013±0.0002 mg/kg/hour. 40 minutes before the end of the operation, nefopam is administered with 20 mg IM. In the postoperative period, infusion is performed in the epidural space: ropivacaine 2 mg/ml+fentanyl 4 mcg/ml+epinephrine 2 mcg/ml, injection rate 4-6 ml/h for 2 days. Then, the mixture reduces the concentration of ropivacaine to 0.2% and continues infusion to 5-7 days, at a rate of 4-6 ml/h. At occurrence of the first complaints on painful sensations prescribe nefopam of 20 mg im/m and continue its appointment in a dose of 20 mg 2 times a day for 5 days and lornoxicam 8 mg intravenously - 2 times/day and pregabalin 75 mg orally - 2 times/day for 5 days. In case of ineffectiveness of this therapy, morphine is prescribed 10 mg IM.EFFECT: invention allows to reduce the frequency of development of acute PTPS, its intensity, to reduce the postoperative need for opioid analgesics and to reduce the frequency of development of chronic PTPS.2 ex
Transdermal system containing non-steroidal anti-inflammatory drug // 2618413
FIELD: medicine, pharmacy.SUBSTANCE: invention relates to medicine. A transdermal system is described comprising an adhesive layer composed of a transdermal preparation on a substrate, wherein the transdermal preparation comprises a) 10 to 40 wt % non-aqueous base material based on the total weight of the transdermal preparation, b) 1 to 10 wt % non-steroidal anti-inflammatory drug based on the total weight of the transdermal prepation and c) a polyethylene glycol component consisting of 0.3 to 5 wt % polyethylene glycol of low molecular weight based on the total weight of the transdermal preparation, and from 1 to 10 wt % polyethylene glycol of high molecular weight to based on the total weight of the transdermal preparation.EFFECT: document describes a transdermal system comprising a non-steroidal anti-inflammatory drug.7 cl, 7 tbl, 36 ex
ethod to stop gastroduodenal bleeding // 2618406
FIELD: medicine.SUBSTANCE: combination of a powdered haemostatic agent and a biologically active granular sorbent is used topically. Therapeutic endoscopy is carried out, during which 0.2 g of powdered polygemostat is first applied to the bleeding defect via a pneumoinsufflator from a distance of 1.5 cm from the defect, and then 0.4 g of anilodiovin is insufflated from a distance of 2.0 cm from the defect to cover the entire bleeding surface.EFFECT: method allows to increase hemostasis reliability and reduce the time of treatment.1 tbl, 2 ex
ethod for hepatic encephalopathy treatment for patients with hepatic cirrhosis // 2618208
FIELD: medicine.SUBSTANCE: for treatment of hepatic encephalopathy in cirrhotic patients, geptral is injected at a dose of 400 mg to 80 mg, daily, for 10 days into the craniopuncture zones: motor, voice zone - I, voice zone - II, voice and psycho-affective - III, two injections per each zone.EFFECT: reduced treatment time while reducing the drug load on the liver and reducing the risk of allergic reactions, more stable remission, effective social adaptation.1 tbl, 3 ex
Composition containing n-acetylcysteine in combination with probiotic bacteria able to restore their own stomach barrier effect lost pharma during pharmacological treatment of gastric hyperacidity // 2617952
FIELD: medicine, pharmacy.SUBSTANCE: pharmaceutical composition for intestinal microflora balance restoration for subjects taking medications for reduction or treatment of gastric hyperacidity. The composition contains effective amounts of bacteria strains Lactobacillus pentosus LPS01 DSM 21980, Lactobacillus plantarum LP01 LMG P-21021, Lactobacillus rhamnosus LR06 DSM 21981 and Lactobacillus delbrueckii LDD 01 (DSMZ 20074) DSM 22106 in combination with N-acetylcysteine. Moreover, these strains are capable of colonizing the stomach at pH of from 4.0 to 5.5, and produce bacteriocins and/or metabolites, and/or hydrogen peroxide. A pharmaceutical composition cntaining effective amounts of the above bacterial strains and a drug belonging to the class of proton pump (PPI) inhibitors are also proposed. The said composition is intended to restore the intestinal microflora balance in subjects taking medications for reduction or treatment of gastric hyperacidity, dyspepsia, gastric ulcer disease and duodenal ulcer disease, gastric ulcer, gastric and duodenal ulcer, duodenal ulcer, gastritis caused by Helicobacter pylori, as well as gastroesophageal reflux disease. Food composition and food supplement with the said strains in effective amounts in combination with N-acetylcysteine are also proposed.EFFECT: group of inventions provides ability to repair stomach own barrier effect lost during pharmacological treatment of gastric hyperacidity, and minimizes the secondary effects of such pharmacological treatment.15 cl, 2 dwg, 6 tbl

Diflunisal co-crystalline form // 2617849
FIELD: pharmacology.SUBSTANCE: diflunisal co-crystalline form with isoniazid is disclosed, wherein the molar ratio of diflunisal to isoniazid is 1:1, wherein the cocrystal has an endothermic spike from 148 to 152°C, according to measurement by differential scanning calorimetry, and spikes at 2θ(°) 5.9, 7.5, 8.5, 11.6, 15.1, 18.5, 26.6, according to measurement by powder X-ray diffraction.EFFECT: diflunisal co-crystalline form is obtained, suitable for use in the pharmaceutical industry as a pharmaceutical preparation component, used to relieve pain accompanied by inflammation, and symptomatic treatment of rheumatoid arthritis and osteoarthritis, with increased level of solubility in water by more than 5 times for diflunisal compared with values in pure form.7 dwg, 2 ex
eans for farm animals postpartum endometritis treatment and prevention // 2617538
FIELD: veterinary medicine.SUBSTANCE: means comprises sodium bicarbonate, citric acid, sodium sulfate, calcium stearate, potato starch, ceftriaxone, carbacholine and aloe extract in the following ratio, wt %: ceftriaxone - 1.0; carbacholine - 0.05; aloe extract - 8.0; sodium bicarbonate - 38,95; citric acid - 32.0; sodium sulfate - 2.0; calcium stearate - 2.0; potato starch - 16.0.EFFECT: means enhances therapeutic efficacy, combines antibacterial, anti-inflammatory, contractive and restoring action.2 tbl, 3 ex
ethod for preparation of drug with amber acid and cetylpyridinium chloride with local action // 2617238
FIELD: pharmacology.SUBSTANCE: invention is a method for topical drug production for periodontal diseases treatment, comprising amber acid, cetyl pyridinium chloride, gelatin, glycerol, 1% solution of NaHCO3 and water, wherein the components are in a certain ratio per one film, in grams, including gelatin soaking in water, which is allowed to stand for 3 hours for swelling, and then heated in a water bath at 60°C until complete dissolution, at that, amber acid is dissolved in 1% solution of NaHCO3 and heated slightly to remove any air bubbles, then cetylpyridinium chloride and glycerol are added gradually to the resulting weight with stirring, and then the resulting solution is added to the cooled gelatin solution at continuous stirring, the mass stirred and left for 1 hour at room temperature to remove air, then a mould treated with 96% ethanol is filled with the resulting mass, which is spread evenly and allowed to stand for 72 hours at room temperature to dry and provide an elastic film.EFFECT: expansion of the arsenal of drugs with prolonged action.1 dwg, 1 tbl, 7 ex

ethod for increasing concentration of avenanthramides in oat grains // 2616873
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry, in particular, to a method of increasing concentration avenanthramides in oat grains including inducing or deepening secondary state of rest in oat grains and soaking of oat grains in secondary state of rest resulting in false malting, as well as whole oat grain with concentration of avenanthramides, which is increased as compared with non-malted grain according to specified method. Use of whole oat grains is also disclosed, which have concentration of avenanthramides increased as compared with non-malted grains according to method for making food product described above. Invention also relates to composition for making food product, nutraceutical or fodder for animals containing oat bran and oat groats without groat shells of whole oat grains with concentration of avenanthramides, which is increased as compared with non-malted grains according to method described above.EFFECT: invention allows to increase concentration of avenanthramides in oat grains.14 cl, 9 dwg, 12 tbl, 10 ex
Anticoagulant // 2616526
FIELD: medicine.SUBSTANCE: anticoagulant containing heparin with activity of 80-120 IU/g, arginine, leucine, taken at a certain ratio.EFFECT: anticoagulant has a more pronounced antilipidemic activity.1 tbl, 4 ex
 
2551141.
Up!